Mohammed Allaw, MD
Internal Medicine · Newburgh, INNPI 1336142728
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 21.9%. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Modernatx, Inc.$1K
- Novartis$1K
- Novo Nordisk$513
- Amgen$345
- GSK$323
- plus $2K from 25 others
Across 438 payments — averaging $8252.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$1.5M
- Bavarian Nordic A/s$589K
- AstraZeneca$542K
- E.r. Squibb & Sons, L.L.C.$250K
- Vertex$172K
- Kowa Research Institute, Inc.$120K
- plus $462K from 11 others
What the payments were for
- Travel & lodging$2,79941%
- Food & beverage$3,98758%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $1,505 |
| Modernatx, Inc. | 8 | $1,307 |
| Novartis | 6 | $1,262 |
| Novo Nordisk | 36 | $513 |
| Amgen(2 entities) | 25 | $345 |
| GSK | 18 | $323 |
| Merck | 19 | $292 |
| AstraZeneca | 14 | $229 |
| Pfizer | 15 | $191 |
| Amarin Pharma, Inc. | 19 | $154 |
| Boehringer Ingelheim | 7 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Astellas Pharma US Inc | 5 | $79 |
| Lilly USA, LLC | 6 | $74 |
| Johnson & Johnson | 3 | $39 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Shield Therapeutics Inc | 2 | $37 |
| Abbott | 2 | $32 |
| Exact Sciences | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Viatris Specialty LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
How this compares
$6,875 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 164 | $186,732 |
| JardianceEmpagliflozin | 146 | $182,882 |
| OzempicSemaglutide | 40 | $49,241 |
| FarxigaDapagliflozin Propanediol | 40 | $42,503 |
| JanuviaSitagliptin Phosphate | 26 | $41,200 |
| Repatha SureclickEvolocumab | 36 | $30,976 |
| TrulicityDulaglutide | 12 | $26,846 |
| GemtesaVibegron | 14 | $15,254 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,018 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,722 |
| MyrbetriqMirabegron | 11 | $5,282 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $4,751 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $4,181 |
| SynthroidLevothyroxine Sodium | 62 | $4,025 |
| Novolog FlexpenInsulin Aspart | 13 | $3,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $191 | $186,732164 claims |
| Boehringer IngelheimJardiance | $93 | $182,882146 claims |
| Novo NordiskOzempic | $513 | $49,24140 claims |
| AstraZenecaFarxiga, Symbicort | $229 | $48,22556 claims |
| MerckJanuvia | $292 | $41,20026 claims |
| Lilly USA, LLCTrulicity | $74 | $26,84612 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $5,28211 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $4,75117 claims |
| AbbVieSynthroid | $1,505 | $4,02562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Newburgh
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.